Israel - Ibrani - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

Israel - Ibrani - Ministry of Health

dexcel ltd, israel - allopurinol - טבליה - allopurinol 300 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Israel - Ibrani - Ministry of Health

dexcel ltd, israel - allopurinol - טבליה - allopurinol 100 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Israel - Ibrani - Ministry of Health

vitamed pharmaceutical industries ltd - dexamethasone as sodium phosphate; neomycin as sulfate; polymyxin b sulfate - טיפות - polymyxin b sulfate 10000 iu/ml; dexamethasone as sodium phosphate 1 mg/ml; neomycin as sulfate 5 mg/ml - dexamethasone and antiinfectives - dexamethasone and antiinfectives - for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics

Israel - Ibrani - Ministry of Health

אלקליל בעמ - איפור

Israel - Ibrani - Ministry of Health

cts ltd - iron as sucroferric oxyhydroxide - טבליות לעיסות - iron as sucroferric oxyhydroxide 500 mg - sucroferric oxyhydroxide

Israel - Ibrani - Ministry of Health

trupharm marketing 1985 ltd. - epinephrine - תמיסה להזרקה - epinephrine 0.3 mg / 0.3 ml - epinephrine

Israel - Ibrani - Ministry of Health

trupharm marketing 1985 ltd. - epinephrine - תמיסה להזרקה - epinephrine 0.15 mg / 0.3 ml - epinephrine

Israel - Ibrani - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 20 mg - afatinib

Israel - Ibrani - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 30 mg - afatinib